Global Digital Therapeutics Market Accelerates Towards $27.3 Billion by 2031 | DataM Intelligence

June 05, 2025 11:00 PM AEST | By EIN Presswire
 Global Digital Therapeutics Market Accelerates Towards $27.3 Billion by 2031 | DataM Intelligence
Image source: EIN Presswire
AUSTIN, TX, UNITED STATES, June 5, 2025 /EINPresswire.com/ -- The Global Digital Therapeutics Market is expected to reach $27.3 billion by 2031, with a strong CAGR of 21.6% between 2024 and 2031. This spike is being driven by the rising frequency of chronic diseases, advances in artificial intelligence (AI) and machine learning (ML), and supportive regulatory frameworks.

Market Overview:

Digital Therapeutics are clinically validated software-based interventions designed to prevent, manage, or treat various medical conditions. These solutions offer scalable and personalized care for conditions such as diabetes, cardiovascular disease, and mental health disorders. By integrating artificial intelligence (AI) and machine learning (ML), these platforms deliver real-time feedback and customized treatment plans, enhancing patient engagement and improving health outcomes.

Download Sample Report Here: https://www.datamintelligence.com/download-sample/digital-therapeutics-market

Market Drivers and Opportunities:

Chronic Disease Prevalence: The increasing prevalence of chronic illnesses such as diabetes and hypertension needs novel management approaches. Digital treatments offer affordable, accessible solutions that can be adjusted to particular patient needs.

AI and ML Integration: Companies like Kaia Health are leveraging AI to offer real-time feedback for musculoskeletal pain management, enhancing the efficacy of digital therapeutics.

Regulatory Support: In 2024, the U.S. Centers for Medicare and Medicaid Services (CMS) proposed new reimbursement codes for digital mental health therapies, signaling increased institutional support for digital therapeutics.

Market Segmentation:

By Product Type:
Software
Devices
Others.

By Application:
Diabetes
Obesity
Cardiovascular Diseases (CVD)
Central Nervous System (CNS) Diseases
Respiratory Diseases
Smoking Cessation
Gastrointestinal Disorders (GID)
Others.

By Sales Channel:

Business-to-Business (B2B):

Employer
Healthcare Providers
Payers
Pharmaceutical Companies
Others.

Business-to-Consumer (B2C):

Patient
Caregiver.

By Region:
North America
Latin America
Europe
Asia Pacific
Middle East
Africa.

Geographical Market Share:

North America: Holding approximately 43.6% of the market share in 2024, North America's dominance is attributed to a patient-centric healthcare approach, improved reimbursement structures, and active collaborations among key players.

Europe: The European market is expanding rapidly, driven by a developed healthcare system and high integration of digital health solutions for treating various diseases.

Asia-Pacific: Countries like Japan are witnessing significant growth due to advancements in digital infrastructure and a growing elderly population requiring chronic disease management solutions.

Key Market Players:

Teladoc Health
2Morrow Inc
Omada Health, Inc.
Resmed Inc
Voluntis, Inc
Kaia Health
Biofourmis
Click Therapeutics, Inc
Welldoc's BlueStar
Lark Technologies, Inc.

These companies are at the forefront of developing innovative digital therapeutic solutions across various health conditions.

Recent Developments:

United States:
Medicare Reimbursement Proposal (2024): CMS proposed new payment codes for digital mental health therapies, potentially increasing adoption and integration into standard care practices.

In 2024, Otsuka Pharmaceutical Co., Ltd. and Click Therapeutics, Inc. received FDA approval for Rejoyn, a mobile application designed to be used alongside medication for the treatment of major depressive disorder.

Japan:
Teijin Pharma and CureApp Collaboration (2024): A joint marketing agreement was established for a prescription digital therapeutic app targeting hypertension, aiming to expand its usage across Japan.

In 2024, Otsuka Pharmaceutical Co., Ltd. established a new subsidiary, Otsuka Precision Health. This new enterprise wants to bring digital therapies such as Rejoyn and other linked health solutions to market, with a particular emphasis on individualized, precision-based healthcare.

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription

Conclusion:

The Digital Therapeutics Market is expected to increase significantly, owing to technological advancements, rising chronic disease prevalence, and favorable regulatory conditions. As stakeholders continue to invest in and implement these novel technologies, digital therapies will become a fundamental part of modern healthcare delivery systems.

Related Reports:

Medical Aesthetics Market

Wearable Health Devices Market

Sai Kiran
DataM Intelligence 4Market Research
+1 877-441-4866
[email protected]
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.